New patent for Pfizer drug IBRANCE

Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/

Annual Drug Patent Expirations for IBRANCE
Annual Drug Patent Expirations for IBRANCE

Ibrance is a drug marketed by Pfizer and is included in two NDAs. It is available from two suppliers. There are six patents protecting this drug and one Paragraph IV challenge.

Drug patent litigation for IBRANCE.

This drug has one hundred and forty-seven patent family members in fifty-five countries.

The generic ingredient in IBRANCE is palbociclib. Two suppliers are listed for this compound. Additional details are available on the palbociclib profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

» Start Your Free Trial Today «

Copyright © DrugPatentWatch. Originally published at
DrugPatentWatch - Make Better Decisions
Scroll to Top